Is Sangamo Therapeutics Inc (SGMO) overvalued? · rev $57.8M
Sangamo Therapeutics Inc (SGMO) is a biotechnology company listed on NASDAQ.
This page asks whether Sangamo Therapeutics Inc (SGMO) looks expensive on cached numbers — not a short thesis.
Latest reported SGMO revenue for 2024-12-31 was $57.8M. Net income was -$97.9M. Revenue was down 67.2% from 2023-12-31 to 2024-12-31. SGMO currently screens at market cap $74.6M.
SGMO currently screens at market cap $74.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SGMO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SGMO stock page for the full model, not this heading.
Not investment advice.